Literature DB >> 19826823

Scoring evaluation for histopathological features of synovium in patients with rheumatoid arthritis during anti-tumor necrosis factor therapy.

Hajime Yamanaka1, Ken-ichiro Goto, Kazutoshi Miyamoto.   

Abstract

The present study was performed to evaluate the synovium in patients with rheumatoid arthritis (RA) treated with anti-tumor necrosis factor alpha agents (anti-TNFalpha). Synovial tissue specimens were obtained during total knee arthroplasty (TKA) from 42 RA patients (12 men, 30 women). Twenty-one RA patients were given anti-TNFalpha agents (infliximab, n = 12; etanercept, n = 9), while the remaining 21 RA patients were given no such agents.The histopathological findings were compared between specimens from these groups using the histological scoring system reported by Rooney, which consists of six items:degree of synovial hyperplasia, fibrosis, number of blood vessels, perivascular lymphocyte infiltration, focal aggregates of lymphocytes, and diffuse infiltrates of lymphocytes.Clinical laboratory data including C-reactive protein(CRP), matrix metalloproteinase-3 (MMP-3), and disease activity scores including a 28-joint count (DAS28), disease duration, methotrexate (MTX) dose, and glucocorticoid dose were also assessed before surgery. There were no significant differences in total score between anti-TNFalpha and no anti-TNFalpha groups. However, significant differences were observed in scores of synoviocyte hyperplasia and perivascular infiltrates of lymphocytes between the groups. These results suggested that these agents have a suppressive effect on cell proliferation in the lining layer and on perivascular lymphocyte infiltration. However, further studies are necessary to elucidate the mechanisms of these effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19826823     DOI: 10.1007/s00296-009-1158-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.

Authors:  P C Taylor; A M Peters; E Paleolog; P T Chapman; M J Elliott; R McCloskey; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  2000-01

3.  Analysis of the histologic variation of synovitis in rheumatoid arthritis.

Authors:  M Rooney; D Condell; W Quinlan; L Daly; A Whelan; C Feighery; B Bresnihan
Journal:  Arthritis Rheum       Date:  1988-08

4.  Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

Authors:  Désirée van der Heijde; Lars Klareskog; Vicente Rodriguez-Valverde; Catalin Codreanu; Horatiu Bolosiu; Jose Melo-Gomes; Jesus Tornero-Molina; Joseph Wajdula; Ronald Pedersen; Saeed Fatenejad
Journal:  Arthritis Rheum       Date:  2006-04

5.  Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair.

Authors:  T C T M van der Pouw Kraan; F A van Gaalen; T W J Huizinga; E Pieterman; F C Breedveld; C L Verweij
Journal:  Genes Immun       Date:  2003-04       Impact factor: 2.676

6.  Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.

Authors:  P P Tak; P C Taylor; F C Breedveld; T J Smeets; M R Daha; P M Kluin; A E Meinders; R N Maini
Journal:  Arthritis Rheum       Date:  1996-07

7.  Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.

Authors:  A I Catrina; J Lampa; S Ernestam; E af Klint; J Bratt; L Klareskog; A-K Ulfgren
Journal:  Rheumatology (Oxford)       Date:  2002-05       Impact factor: 7.580

8.  Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.

Authors:  Anca Irinel Catrina; Christina Trollmo; Erik af Klint; Marianne Engstrom; Jon Lampa; Ylva Hermansson; Lars Klareskog; Ann Kristin Ulfgren
Journal:  Arthritis Rheum       Date:  2005-01

9.  Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study.

Authors:  H Mielants; E M Veys; S Goemaere; K Goethals; C Cuvelier; M De Vos
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

10.  Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue.

Authors:  Tom J M Smeets; Maarten C Kraan; Marieke E van Loon; Paul-Peter Tak
Journal:  Arthritis Rheum       Date:  2003-08
View more
  4 in total

1.  Feasibility study of semi-automated measurements of finger joint space widths.

Authors:  Alexander Pfeil; Julia Sommerfeld; Rosemarie Fröber; Gabriele Lehmann; Ansgar Malich; Andreas Hansch; Gunter Wolf; Joachim Böttcher
Journal:  Rheumatol Int       Date:  2010-04-17       Impact factor: 2.631

2.  Pathological features of established osteoarthritis with hydrathrosis are similar to rheumatoid arthritis.

Authors:  Kensuke Koyama; Tetsuro Ohba; Toru Odate; Masanori Wako; Hirotaka Haro
Journal:  Clin Rheumatol       Date:  2020-10-08       Impact factor: 2.980

3.  Naringenin mitigates titanium dioxide (TiO2)-induced chronic arthritis in mice: role of oxidative stress, cytokines, and NFκB.

Authors:  Marília F Manchope; Nayara A Artero; Victor Fattori; Sandra S Mizokami; Dimitrius L Pitol; João P M Issa; Sandra Y Fukada; Thiago M Cunha; José C Alves-Filho; Fernando Q Cunha; Rubia Casagrande; Waldiceu A Verri
Journal:  Inflamm Res       Date:  2018-10-28       Impact factor: 4.575

4.  Development of Standardized Fetal Progenitor Cell Therapy for Cartilage Regenerative Medicine: Industrial Transposition and Preliminary Safety in Xenogeneic Transplantation.

Authors:  Alexis Laurent; Philippe Abdel-Sayed; Aurélie Ducrot; Nathalie Hirt-Burri; Corinne Scaletta; Sandra Jaccoud; Katja Nuss; Anthony S de Buys Roessingh; Wassim Raffoul; Dominique Pioletti; Brigitte von Rechenberg; Lee Ann Applegate; Salim Darwiche
Journal:  Biomolecules       Date:  2021-02-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.